Trials / Terminated
TerminatedNCT01163071
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
Detailed description
Dose limiting toxicities (DLT), maximum tolerated dose (MTD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-011 | ABI-011 |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-09-23
- Completion
- 2011-09-23
- First posted
- 2010-07-15
- Last updated
- 2019-11-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01163071. Inclusion in this directory is not an endorsement.